Short Interest in Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Drops By 38.2%

Key Points

• Short interest in Basilea Pharmaceutica AG declined by 38.2% in September, falling to 9,400 shares from 15,200 shares at the end of August.
• Zacks Research upgraded Basilea Pharmaceutica's stock to a "hold" rating, contributing to an overall average rating of "hold" from analysts.
• The stock is currently priced at $67.75, with a 12-month low of $47.50 and a high of $67.75, indicating stable performance in the market.

Basilea Pharmaceutica AG (OTCMKTS:BPMUF - Get Free Report) was the target of a large decline in short interest in September. As of September 15th, there was short interest totaling 9,400 shares, a decline of 38.2% from the August 31st total of 15,200 shares. Based on an average trading volume of 0 shares, the short-interest ratio is currently ∞ days. Based on an average trading volume of 0 shares, the short-interest ratio is currently ∞ days.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded shares of Basilea Pharmaceutica to a "hold" rating in a research report on Wednesday, September 24th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the company presently has an average rating of "Hold".

Basilea Pharmaceutica Stock Performance

OTCMKTS:BPMUF opened at $67.75 on Friday. Basilea Pharmaceutica has a 12 month low of $47.50 and a 12 month high of $67.75. The company's 50-day moving average price is $67.49 and its two-hundred day moving average price is $58.46.

About Basilea Pharmaceutica

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.